Glucagon is a natural hormone made by the pancreas that raises blood sugar by releasing glucose stored in the liver.1 It has been FDA-approved since 1960. The label cited here covers two uses that must not be confused: Gvoke to treat severe low blood sugar in people with diabetes aged 2 and older, and Gvoke VialDx as a diagnostic aid that briefly stops gut movement during X-ray examinations in adults.1,2 Its approval for severe low blood sugar rests on smaller controlled crossover studies in which nearly all participants’ blood sugar rose to the target within 30 minutes.1
Glucagon at a glance
What it is
A peptide hormone. The label states that glucagon raises blood sugar by activating glucagon receptors in the liver, which releases stored glucose.1
FDA status
FDA-approved. Drugs@FDA lists the first glucagon application with an approval date of November 14, 1960, and Gvoke with an approval date of September 10, 2019. The cited label has no boxed warning.1,2,5
Human evidence
Two randomized crossover studies in 80 and 81 adults with type 1 diabetes and a study in 31 children, described in the label.1
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is glucagon?
Glucagon is a peptide hormone that the body makes in the pancreas. Lab-made glucagon is used as a medicine.1
Drugs@FDA lists several glucagon applications, including Eli Lilly’s original application approved in 1960, Fresenius Kabi’s glucagon, Baqsimi and Gvoke.2,3,4,5
How does glucagon work?
The label states that glucagon raises blood sugar by activating glucagon receptors in the liver, which breaks down stored glycogen and releases glucose. It needs liver glycogen stores to work.1
The label also states that glucagon relaxes the smooth muscle of the stomach and intestines, which is the basis of its diagnostic use.1
What do human studies show?
The label describes two multicenter crossover studies in adults aged 18 to 74 with type 1 diabetes, with 80 and 81 participants, in which blood sugar was lowered with insulin and each participant received Gvoke and another glucagon product at separate visits.1
Treatment success, defined as a predefined rise in blood sugar within 30 minutes, occurred in 98.7% of the Gvoke group and 100% of the comparison group, meeting the studies’ non-inferiority margin, according to the label.1
In a study of 31 children with type 1 diabetes, all 30 evaluable children reached the target rise in blood sugar, according to the label.1
What the evidence base contains
Controlled human trial Two multicenter randomized crossover studies in adults with type 1 diabetes (80 and 81 participants) that compared Gvoke with another glucagon product after blood sugar was lowered with insulin.1
Small, short, or incompletely reported human study A study in 31 children with type 1 diabetes, all evaluable participants of whom reached the target rise in blood sugar.1
Yes. Drugs@FDA lists Eli Lilly’s glucagon application with an approval date of November 14, 1960, Baqsimi with an approval date of July 24, 2019, and Gvoke with an approval date of September 10, 2019.2,4,5
The Gvoke and Gvoke VialDx label cited here (DailyMed SPL version 2, published July 9, 2026) states that Gvoke is indicated for severe hypoglycemia in adults and children aged 2 and older with diabetes, and that Gvoke VialDx is indicated as a diagnostic aid during radiologic examinations to temporarily stop movement of the gastrointestinal tract in adults.1
The label has no boxed warning. It states that glucagon is contraindicated in people with pheochromocytoma, insulinoma or a prior allergic reaction to it, and that diagnostic use is also contraindicated in people with glucagonoma.1
Its warnings cover a large rise in blood pressure with pheochromocytoma, low blood sugar with insulinoma or glucagonoma, serious allergic reactions, lack of effect when liver glycogen is depleted, a skin rash called necrolytic migratory erythema, and, for diagnostic use, high blood sugar in people with diabetes and increases in blood pressure and heart rate in people with heart disease.1
Timeline
FDA approves Eli Lilly’s glucagon application, according to Drugs@FDA.2
FDA approves Fresenius Kabi’s glucagon application, according to Drugs@FDA.3
DailyMed publishes the Gvoke and Gvoke VialDx label version cited on this page.1
What is still unknown?
How well it works when liver glycogen is low, for example during starvation or long-lasting low blood sugar: the label warns that it may not be effective then.1
How other glucagon products compare: this page cites one label covering Gvoke and Gvoke VialDx, and other glucagon products have their own labels.1,3,4
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Glucagon: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Glucagon are the records PeptideScanner has selected and published, not every registration or paper about Glucagon. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
FDA-approved as Gvoke, Baqsimi and other glucagon products. Smaller controlled crossover studies described in the label found that nearly all participants reached the target rise in blood sugar within 30 minutes. The label keeps the severe-hypoglycemia and diagnostic uses separate.↗↗↗↗
Review source snapshots checked September 20, 2026 · Integrity checked September 20, 2026.
Three selected reports examine glucagon rescue formulations in diabetes. Nasal, intramuscular and ready-to-use subcutaneous products have different delivery contexts; related analogues and diagnostic uses require separate assessment.↗↗↗
What the reviewed sources report
Controlled studies found high recovery rates after experimentally induced hypoglycemia. A small uncontrolled study also reported recovery during spontaneous episodes. Laboratory recovery times and trained-caregiver observations do not establish equivalent performance in every emergency.↗↗↗
What remains unresolved?
How do current product labels distinguish rescue and diagnostic uses and age-specific indications?↗↗↗
What do larger real-world studies establish about failures, harms and untrained-caregiver use?↗↗↗
The shared label separates Gvoke for severe hypoglycemia in adults and children aged two years and older with diabetes from Gvoke VialDx as a diagnostic aid during gastrointestinal radiologic examinations in adults. These are different product uses; the diagnostic vial is not the severe-hypoglycemia presentation. Label: 1.1, 1.2 ↗
Which safety limits matter?
Contraindications include pheochromocytoma, insulinoma and prior hypersensitivity; diagnostic use also contraindicates glucagonoma. Warnings address serious allergic reactions, blood-pressure increases, hypoglycemia in specific tumor settings, reduced efficacy when liver glycogen is depleted, and a skin reaction reported with continuous infusion. Diagnostic use has additional warnings about hyperglycemia and increased cardiac demand, blood pressure and heart rate. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 8a7eea4413fc92f6e205eb71e1c76b56e2ae78d9fe5eb31679c7319800c12d49. Extracted XML SHA-256: aaa5ae4cd4355c3558a0223bcca2f00eabc45db6667177ac9561b0b4db5c95ba.
Three selected reports examine glucagon rescue formulations in diabetes. Nasal, intramuscular and ready-to-use subcutaneous products have different delivery contexts; related analogues and diagnostic uses require separate assessment.123
Bottom line from this bounded source set
Controlled studies found high recovery rates after experimentally induced hypoglycemia. A small uncontrolled study also reported recovery during spontaneous episodes. Laboratory recovery times and trained-caregiver observations do not establish equivalent performance in every emergency.123
Reviewed study record
Nasal versus intramuscular glucagon
Design
Randomized crossover noninferiority study after experimentally induced hypoglycemia.1
Population
The primary efficacy analysis included 66 adults with type 1 diabetes who received both formulations.1
Outcomes reported
Both formulations achieved treatment success in all 66 evaluable participants within 25 minutes. Mean time to success was 11.4 minutes with nasal and 9.9 minutes with intramuscular glucagon.1
Limitations
The induced-hypoglycemia setting and controlled administration differ from an unplanned emergency. Recovery speed is distinct from preparation time and caregiver usability.1
Reviewed study record
Ready-to-use autoinjector versus emergency kit
Design
Two randomized crossover noninferiority studies after insulin-induced hypoglycemia.2
Population
161 adults with type 1 diabetes participated across the studies.2
Outcomes reported
The ready-to-use product met the prespecified noninferiority comparison. Mean time from administration to recovery was 13.8 versus 10.0 minutes; preparation and administration took 27.3 versus 97.2 seconds. Adverse-event profiles were reported as comparable.2
Limitations
Two studies share one publication. Administration-to-recovery and total preparation-plus-recovery intervals answer different questions; these results are not a product recommendation.2
Reviewed study record
Nasal glucagon during spontaneous episodes
Design
Prospective open-label real-world study with trained caregivers and no randomized comparator.3
Population
69 adults experienced 157 evaluable moderate or severe hypoglycemia episodes.3
Outcomes reported
Caregivers reported resolution within 30 minutes in 95.7% of patients. All 12 severe episodes resolved within 15 minutes.3
Limitations
Repeated episodes within people are not independent participants. Caregiver assessment, training and lack of a comparator limit causal and comparative conclusions.3
No registered Crossref update in the reviewed snapshotChecked September 20, 2026 for DOI 10.1007/s13300-020-00845-7. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1136/bmjdrc-2021-002137. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.13278. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The pivotal question was recovery from hypoglycemia
EMA’s Ogluo review describes controlled studies of glucagon in people with diabetes. The pivotal adult endpoint was blood-glucose recovery within 30 minutes; the pediatric study was open-label. EMA PDF pp. 106, 107 ↗
More findings, study links and document coverage
Noninferiority did not mean identical recovery speed
The adult study met its noninferiority criterion, but EMA reported slower glucose recovery after administration than the reference product. Preparation time and the time measured after injection are distinct comparisons. EMA PDF pp. 107, 108 ↗
Usability studies answer a different question
Human-factors studies tested successful device use, including simulated emergencies. Their results support a usability assessment; they are not the same as observing clinical outcomes during spontaneous severe hypoglycemia. EMA PDF pp. 107, 108, 111 ↗
The formulation and population define the scope
This assessment concerns the ready-to-use Ogluo formulation and its severe-hypoglycemia indication. A real-world actual-use study was planned; that plan is not a completed result in this document. EMA PDF pp. 108, 112 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
European medicine records · 2 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: Glucagon. EMA record ↗
Marketing authorisation: 2019-12-16. EMA metadata last updated 2025-09-15. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Targeted nasal, autoinjector and ready-to-use glucagon search, not the complete physiological or clinical glucagon literature. Analog medicines are separate identities.
93 retrieved · 3 included · 0 excluded · 90 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"glucagon"[Title] AND ("nasal"[Title/Abstract] OR "autoinjector"[Title/Abstract] OR "ready-to-use"[Title/Abstract])
Full-text appraisal and screening of unassessed records remain open.
Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.
Showing 25 of 93 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 34620618 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT03439072; NCT02656069.
PubMed 32514794 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT03339453.
PubMed 29504662 — include: Selected human report; abstract and record metadata reviewed. Study families: glucagon-PMID29504662-registry-linkage-unresolved.
PubMed 42557738 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42444066 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41022041 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41767683 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42041268 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 40459429 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 39490582 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 39614598 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 39341285 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 37291796 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 39235687 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 38972099 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 39086086 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 38736200 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 38224759 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 38444629 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 37867226 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 38000667 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 37751153 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 37707700 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 35533142 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 37268778 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
12 retrieved · 12 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 12 of 12 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA020918 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON HYDROCHLORIDE.
FDA ANDA071022 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON HYDROCHLORIDE.
FDA ANDA071023 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON HYDROCHLORIDE.
FDA NDA212097 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON.
FDA ANDA204468 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON.
FDA NDA201849 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON HYDROCHLORIDE.
FDA NDA020928 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON.
FDA NDA210134 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON.
FDA ANDA214457 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON.
FDA NDA012122 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON HYDROCHLORIDE.
FDA ANDA218813 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON.
FDA ANDA208086 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: GLUCAGON.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/005391 — include: EMA feed product Ogluo; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/003848 — include: EMA feed product Baqsimi; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
36 retrieved · 17 included · 0 excluded · 19 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 36 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 46681 — include: Document linked by EMA product number; content unappraised. Baqsimi : EPAR - All authorised presentations
EMA 46684 — include: Document linked by EMA product number; content unappraised. Baqsimi : EPAR - Public assessment report
EMA 50302 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR - Medicine overview
EMA 50304 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR - All authorised presentations
EMA 50305 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR - Public assessment report
EMA 50306 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR - Risk Management Plan
EMA 65060 — include: Document linked by EMA product number; content unappraised. Baqsimi-H-C-003848-P46-002 : EPAR - Assessment report
EMA 54196 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 68321 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR – Product information - tracked changes
EMA 46683 — include: Document linked by EMA product number; content unappraised. Baqsimi : EPAR - Risk management plan
EMA 46682 — include: Document linked by EMA product number; content unappraised. Baqsimi : EPAR - Medicine overview
EMA 51804 — include: Document linked by EMA product number; content unappraised. Baqsimi : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 70088 — include: Document linked by EMA product number; content unappraised. Baqsimi : EPAR - Procedural steps taken and scientific information after authorisation
EMA 70089 — include: Document linked by EMA product number; content unappraised. Baqsimi-VR-0000244909 : EPAR - Assessment report - Variation
EMA 68320 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR - Procedural steps taken and scientific information after authorisation
EMA 50303 — include: Document linked by EMA product number; content unappraised. Ogluo : EPAR - Product information
EMA 46680 — include: Document linked by EMA product number; content unappraised. Baqsimi : EPAR - Product information
EMA 3649 — not screened: Title-name match awaiting identity and document review. EU/3/17/1887: Public summary of opinion on orphan designation: Synthetic glucagon analogue modified to contain 7 amino acid substitutions for the treatment of congenital hyperinsulinism
EMA 8202 — not screened: Title-name match awaiting identity and document review. EU/3/18/2022: Public summary of opinion on orphan designation: Glucagon analogue linked to a human immunoglobulin Fc fragment for the treatment of congenital hyperinsulinism
EMA 22861 — not screened: Title-name match awaiting identity and document review. EU/3/14/1342: Public summary of opinion on orphan designation: Glucagon for the treatment of congenital hyperinsulinism
EMA 35129 — not screened: Title-name match awaiting identity and document review. EU/3/01/077: Public summary of positive opinion for orphan designation of [gly2]-recombinant human glucagon-like peptide for the treatment of short-bowel syndrome
EMA 41458 — not screened: Title-name match awaiting identity and document review. EU/3/12/960: Public summary of opinion on orphan designation: Glucagon for the treatment of congenital hyperinsulinism
EMA 43803 — not screened: Title-name match awaiting identity and document review. EU/3/18/2091: Public summary of opinion on orphan designation: Glucagon for the treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome
EMA 44117 — not screened: Title-name match awaiting identity and document review. EU/3/18/2126: Public summary of opinion on orphan designation: Human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment for the treatment of short bowel syndrome
EMA 48608 — not screened: Title-name match awaiting identity and document review. EU/3/20/2275: Public summary of positive opinion for orphan designation of glucagon analogue linked to a human immunoglobulin Fc fragment for the treatment of insulin autoimmune syndrome
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
11 retrieved · 3 included · 8 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 11 of 11 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EU/3/18/2091 — include: EMA orphan feed identifies Glucagon; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/14/1342 — include: EMA orphan feed identifies Glucagon; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/12/960 — include: EMA orphan feed identifies Glucagon; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/22/2619 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
EMA EU/3/01/077 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
EMA EU/3/21/2561 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
EMA EU/3/21/2547 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
EMA EU/3/17/1887 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
EMA EU/3/20/2275 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
EMA EU/3/18/2022 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
EMA EU/3/18/2126 — exclude: Different analogue, conjugate or glucagon-like peptide; the name match does not identify the unmodified catalog molecule.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
3307 retrieved · 0 included · 0 excluded · 3307 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Glucagon" OR "Gvoke VialDx" OR "Ogluo" OR "Baqsimi"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 3307 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT03690206 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05377333 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06546384 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06500143 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01595789 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04079855 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07806838 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01421147 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01162876 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01801540 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02673138 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03203915 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06972238 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01507285 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00273000 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02792400 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00861809 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02081001 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05463744 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07786675 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07098663 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04518930 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03482830 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02561130 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01503112 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Glucagon?
FDA-approved as Gvoke, Baqsimi and other glucagon products. Smaller controlled crossover studies described in the label found that nearly all participants reached the target rise in blood sugar within 30 minutes. The label keeps the severe-hypoglycemia and diagnostic uses separate.↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 119 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
10
FDA Federal Register documents
16
DailyMed SPL versions
2
Canonical profile
Published
Profile structured data
Published
Linked dated records
315
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsSource records by collection · 315 dated records
PubMed revised the bibliographic metadata of PMID 42270043, with a metadata revision date of 2026-10-28. This version reports that observation; the earlier retained observation remains available as version 1.
PubMed revised the bibliographic metadata of PMID 42400596, with a metadata revision date of 2026-11-04. This version reports that observation; the earlier retained observation remains available as version 1.
We added a plain-language reader guide with cited answers, re-checked the Gvoke and Gvoke VialDx label, and added Drugs@FDA approval records for glucagon products.
Selected records span November 14, 1960 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PubMed lists PMID 42837671 in Clinical and translational gastroenterology as Journal Article, with publication-date metadata of 2026-10-06 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 43013397 in Cell reports as Journal Article, with publication-date metadata of 2026-11-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42789963 in American journal of physiology. Renal physiology as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42912619 in Biomacromolecules as Journal Article, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42886203 in Journal of diabetes investigation as Journal Article, with publication-date metadata of 2026-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42845437 in bioRxiv : the preprint server for biology as Journal Article, Preprint, with publication-date metadata of 2026-08-14 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42822764 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2026-10-01 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 42332291 in Cellular and molecular life sciences : CMLS as Journal Article, with publication-date metadata of 2026-06-22 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 40513916 in American journal of preventive medicine as Journal Article, with publication-date metadata of 2025-06-11 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PubMed lists PMID 39925097 in American journal of physiology. Endocrinology and metabolism as Journal Article, with publication-date metadata of 2025-02-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗